S&P Global recently released the 2025 Corporate Sustainability Assessment (CSA) score results for Fosun International Limited (HKEX stock code: 00656, “Fosun International” or “Fosun”). Fosun International’s S&P Global CSA score has risen to 72 points, significantly outperforming the industry average and maintaining its leading position in the industry.

September 29, 2025, Jeddah, Saudi Arabia – The inauguration ceremony for the Fosun Pharma Middle East Office and Fosunhenlius Middle East United Company was grandly held in Jeddah, Saudi Arabia. This move marks a significant step in Fosun Pharma's localized operations in the Middle East, representing a strategic initiative by the company to continuously expand its global presence through innovation.

SHANGHAI, China & JERSEY CITY, NJ – SEPTEMBER 19, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS^® (denosumab) injection 60 mg/mL and BILPREVDA^® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.

On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International” or the “Company”) was informed that in the 2025 Sustainability Ratings of listed companies released by Hang Seng Indexes Company, Fosun International received an AA- rating for the third consecutive year.

Centering its strategic focus on “business streamlining, adopting an asset-light strategy and collaborating with key partners, achieving balanced investment and divestment”, Fosun International (00656.HK) has sustained steady business development amid a complex global environment.

On September 11, The Asset, a leading financial magazine in the Asia-Pacific region, published an exclusive interview with Chen Qiyu, Co-CEO of Fosun International. The article highlighted Fosun’s performance in its 2025 interim results, as well as the company’s ongoing progress in global expansion and innovation-driven development.

On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Company”) held the signing ceremony for its 2025 three-year sustainability-linked syndicated loan in Hong Kong.

On 9 September, Fortune China magazine released its 2025 list of “Most Admired Chinese Companies”, in which Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was included in the Industry Star List.

Shanghai, China, September 8, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for its HLX17, a proposed pembrolizumab biosimilar independently developed by the company, was approved by the U.S. Food and Drug Administration (FDA) as an adjuvant therapy for certain resected solid tumors,